Olmesartán/Amlodipino/Hidroclorotiazida Combix (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxomil / amlodipine / hydrochlorothiazide, the active ingredient in Olmesartán/Amlodipino/Hidroclorotiazida Combix, is a combination antihypertensive presented as a tablet for oral use. It is indicated for the management of high blood pressure in adult patients, helping to lower cardiovascular risk.

GNH USA supplies Olmesartán/Amlodipino/Hidroclorotiazida Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU quality standards and is manufactured under strict Good Manufacturing Practice. It is available for bulk distribution and can be integrated into national formularies.

Olmesartan/amlodipine/hydrochlorothiazide is a combination antihypertensive used to manage elevated blood pressure.

- Essential hypertension: lowers systolic and diastolic pressure in patients with primary high blood pressure. - Resistant hypertension: provides additional control when single‑agent therapy is insufficient. - Hypertension with fluid retention: adds a thiazide diuretic to reduce plasma volume alongside vasodilatory effects.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Peripheral edema, especially of the ankles. - Flushing or warmth sensation. - Fatigue or mild weakness. - Increased urination.

Serious or Rare Side Effects: - Angioedema or severe swelling of the face, lips, tongue, or throat. - Marked hypotension leading to fainting. - Acute kidney injury or significant rise in serum creatinine. - Electrolyte disturbances such as severe hypokalemia or hyponatremia. - Pancreatitis or severe abdominal pain. - Liver enzyme elevations indicating hepatic injury.

Before initiating therapy, consider the following precautions: - Monitor blood pressure regularly to assess efficacy and avoid excessive hypotension. - Assess renal function and electrolytes, especially potassium, before and during treatment. - Use caution in patients with severe hepatic impairment; dose adjustment may be required. - Elderly patients may be more sensitive to blood‑pressure changes and fluid loss. - Avoid abrupt discontinuation; taper under medical supervision if therapy needs to be stopped. - Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Olmesartan/amlodipine/hydrochlorothiazide can interact with several medicines.

Major Interactions (Avoid): - Aliskiren in patients with diabetes or renal impairment, which can increase the risk of renal dysfunction. - Potassium‑sparing diuretics or supplements, potentially causing hyperkalemia. - Lithium, as thiazide diuretics may raise lithium levels and toxicity risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs), which may blunt antihypertensive effect and affect renal function. - ACE inhibitors or other ARBs, increasing risk of hyperkalemia and renal impairment. - Antidiabetic agents, as improved blood pressure control may enhance glucose lowering. - CYP3A4 inhibitors or inducers, which can alter amlodipine plasma concentrations.